The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted healthcare providers, importers, distributors, retailers, and parents following the recall of approximately 90,000 bottles of Children’s Ibuprofen Oral Suspension in the United States over concerns about contamination with foreign materials.
The safety notification follows a recall initiated after reports from consumers who discovered unusual particles and abnormal substances inside the medicine, raising concerns about product quality and safety. The affected product is a children’s pain and fever medication commonly used to manage symptoms associated with colds, flu, sore throat, headaches, and toothaches.
Although the recalled medicine was distributed within the United States, Nigerian health authorities have moved to prevent any affected batches from entering the local supply chain through authorised or unauthorised channels. Brandspur Banking News Desk reports that NAFDAC has directed its officials across the country to intensify market surveillance and remove the product if discovered in circulation.
The recalled product is Children’s Ibuprofen Oral Suspension, USP, with a strength of 100mg per 5ml and packaged in 120ml bottles. The affected batches are identified by lot numbers 7261973A and 7261974A, with an expiry date of January 31, 2027. The medicine was manufactured by Strides Pharma Inc. in India for the United States market.
Health experts warn that contamination in oral medicines may compromise effectiveness and create potential health risks, particularly for children. Depending on the nature of the foreign material, users could experience adverse reactions or other medical complications requiring professional attention.
NAFDAC advised healthcare facilities, pharmacies, distributors, and retailers to review their inventories immediately and isolate any affected stock if identified. The agency also urged consumers and caregivers to obtain medicines only from licensed and authorised sources to reduce the risk of exposure to compromised products.
Parents who may have purchased or administered the affected medicine to their children have been encouraged to discontinue use and seek medical advice if any unusual symptoms or reactions occur.
The latest alert highlights ongoing international cooperation between drug regulators and underscores NAFDAC’s efforts to strengthen medicine safety monitoring in Nigeria as authorities work to protect consumers from potentially unsafe pharmaceutical products entering the market.
